Adam Levy - Jul 28, 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
CFO and Secretary
Signature
/s/ Adam Levy
Stock symbol
MLYS
Transactions as of
Jul 28, 2025
Transactions value $
-$1,077,477
Form type
4
Date filed
7/30/2025, 08:12 PM
Previous filing
Jul 15, 2025
Next filing
Oct 15, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Levy Adam Scott CFO and Secretary 150 N. RADNOR CHESTER ROAD,, SUITE F200, RADNOR /s/ Adam Levy 2025-07-30 0001693134

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Sale -$182K -12.9K -6.27% $14.04 194K Jul 28, 2025 Direct F1
transaction MLYS Common Stock Sale -$11.3K -807 -0.42% $14.00 193K Jul 29, 2025 Direct F2
transaction MLYS Common Stock Sale -$757K -51.5K -26.7% $14.70 141K Jul 30, 2025 Direct F3
transaction MLYS Common Stock Sale -$127K -8.43K -5.96% $15.10 133K Jul 30, 2025 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.20. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.01. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.06 to $15.06. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.063 to $15.130. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.